Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2026

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

• Paroxysmal Nocturnal Hemoglobinuria (PNH) market size has reached to $4.67 billion in 2025 • Expected to grow to $7.42 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Rising Prevalence Of Blood And Bone Marrow Disorders Fueling The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market • Market Trend: Innovative Therapeutic Advancements Lead The Way In Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment • North America was the largest region in 2025.

What Is Covered Under Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

Paroxysmal nocturnal hemoglobinuria (PNH) refers to a rare and acquired hematological disorder characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins on the surface of blood cells. It is a debilitating disorder that leads to premature death and impaired production of blood cells. PNH includes a wide range of symptoms, such as fatigue, shortness of breath, abdominal pain and thrombosis (blood clot formation). The main types of treatments included in paroxysmal nocturnal hemoglobinuria (PNH) are medications, bone marrow transplantation, blood transfusion, immunosuppressive therapy and others. Medications refer to substances that are specifically designed and formulated to diagnose, treat, prevent, or alleviate medical conditions, diseases, or symptoms in humans and animals. Various types of diagnosis include flow cytometry, high-resolution mass spectrometry and others, which are used by several end users, including hospitals, clinics and others.

What Is The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Growth Forecast?

The paroxysmal nocturnal hemoglobinuria (pnh) market size is expected to see strong growth in the next few years. It will grow to $7.42 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to development of next-generation complement inhibitors, increasing diagnosis rates through advanced testing, growing focus on orphan disease treatment, rising access to specialized hematology centers, expansion of reimbursement coverage for rare disease therapies. Major trends in the forecast period include rising adoption of complement inhibitor therapies, increasing use of flow cytometry for accurate diagnosis, growth of long-acting monoclonal antibody treatments, expansion of specialized rare hematology care programs, improved management of thrombosis and hemolysis complications.

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Segmentation

1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types 2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types 3) By End Use: Hospitals, Clinics, Other End Users Subsegments: 1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications 2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation 3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion 4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil 5) By Other Treatment Types: Supportive Therapies, Management Of Complications

What Is The Driver Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The rising number of blood disorders and bone marrow-related disorders is expected to propel the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market going forward. Blood disorders are medical conditions that affect the composition, function, and production of blood and its components. Bone marrow-related disorders occur when either insufficient red, white, or platelet production occurs in the bone marrow or when the blood cells that are generated are damaged or defective. PNH is closely related to blood disorders and bone marrow-related disorders due to its impact on blood cell production, immune system function, and the bone marrow microenvironment. It is a rare blood disorder that is related to bone marrow failure diseases and occurs when a genetic flaw affects how red blood cells and platelets work. For instance, according to Blood Cancer United, a UK-based nonprofit advocacy group dedicated to raising awareness and support for blood cancer patients, in 2025, approximately 192,070 individuals in the U.S. are projected to receive a diagnosis of leukemia, lymphoma, or myeloma. Therefore, the rising number of blood disorders and bone marrow-related disorders is driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) industry.

Key Players In The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc, Novartis AG, Thermo Fisher Scientific Inc, GE Healthcare, Grifols S.A, Genentech Inc, Bioverativ Inc, BioCryst Pharmaceuticals, Hansa Biopharma AB, Apellis Pharmaceuticals Inc, Akari Therapeutics Plc, RA Pharmaceuticals Inc, C5 Therapeutics Inc, Omeros Corporation, Amyndas Pharmaceuticals SA, CANbridge Pharmaceuticals, NovelMed Therapeutics Inc, Annexon Inc, Dianthus Therapeutics, DynamiCure Biotechnology, Kira Pharmaceuticals Ltd, Kyowa Kirin Co Ltd, Swedish Orphan Biovitrum AB, Arrowhead Pharmaceuticals, ReAlta Life Sciences, Q32 Bio, ISU Abxis

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Trends and Insights

Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are focusing on developing new and innovative drugs and therapies, such as injectable C5 inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), to sustain their position in the market. An injectable C5 inhibitor is a monoclonal antibody that blocks the complement component C5, reducing inflammation and tissue damage in autoimmune diseases and conditions like paroxysmal nocturnal hemoglobinuria (PNH). For instance, in February 2024, Chugai Pharmaceutical Co., a Japan-based pharmaceutical company, received priority review approval from China's National Medical Products Administration (NMPA) for treating paroxysmal nocturnal hemoglobinuria (PNH). This marks China as the first country to approve PIASKY, ahead of other major markets, allowing it to enter National Reimbursement Drug List (NRDL) negotiations within the same year. PNH, classified as a rare disease, affects an estimated 12,740 individuals in China, presenting significant market potential.

What Are Latest Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

In March 2024, Gilead Sciences, Inc., a US-based biopharmaceutical company that discovers, develops, and sells medicines for life-threatening diseases, acquired Cymabay Therapeutics, Inc. for $4.3 billion. With this acquisition, Gilead Sciences, Inc., aims to enhance its liver disease portfolio by introducing seladelpar, a promising treatment for primary biliary cholangitis that addresses significant unmet medical needs. Cymabay Therapeutics, Inc. is a US-based pharmaceutical company that is developing seladelpar as a potential treatment for paroxysmal nocturnal hemoglobinuria (PNH).

Regional Outlook

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The paroxysmal nocturnal hemoglobinuria (PNH) market consists of revenues earned by entities by providing services such as gene therapy, stem cell transplant and complete blood count test (CBC). The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) market also includes sales of Eculizumab and Ravulizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2026?

The paroxysmal nocturnal hemoglobinuria (pnh) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria (pnh) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.